Search Life Sciences Jobs

AmpliMed Corporation Announces Interim Phase I/II Trial Results For Amplimexon plus Dacarbazine For Treatment Of Malignant Melanoma; Encouraging Data Presented At Perspectives In Melanoma X And The Third International Melanoma Research Congress In The Netherlands

NOORDWIJK, The Netherlands & TUCSON, Ariz.--(BUSINESS WIRE)--Sept. 14, 2006--AmpliMed today announced interim results from the ongoing Phase I/II clinical trial of its lead drug candidate Amplimexon(R) (imexon, inj.) in combination with the drug dacarbazine (DTIC) in patients with advanced malignant melanoma. The results are being presented by study investigator Dr. Jeffrey S. Weber of the USC/Norris Comprehensive Cancer Center at a poster session on September 14th-16th at the Congress of Perspectives in Melanoma X and The Third International Melanoma Research Congress.